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Abstract 
The rarity of malignant pheochromocytoma coupled with the lack of definitive predictors of 
malignancy and the variability of clinical course, poses a significant diagnostic and 
therapeutic challenge. Since data on treatment is so scarce, case reports are a valuable source 
of knowledge for clinicians. 
This case report describes the medical history of a woman, aged 51 at the time of initial 
diagnosis and adrenalectomy. Within over 5 years she presented with recurrent relapse of 
tumour in adrenal gland bed and multiple distant metastases to descending colon, abdominal 
wall, postoperative scars, and the peritoneum. Neither before diagnosis nor during the whole 
follow-up were symptoms associated with pheochromocytoma present. 
The treatment administered to our patient consisted of numerous debulking surgeries along 
with administration of both hot and cold somatostatin analogues. We believe that debulking 
surgeries played a substantial role in enabling the patient to survive nearly 6 years despite 
aggressive clinical course of pheochromocytoma. She passed away in 2012 as a result of 
postlaparotomy complications. 
We stress the role of debulking surgery in the treatment of malignant pheochromocytoma and 
summarise current literature. 
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Introduction 
Pheochromocytoma (pheo) is a rare catecholamine-secreting tumour, although it may 
also be nonfunctional [1]. Its prevalence is less than 5 per 1 million of the general population 
and less than 1% of the hypertensive population, with no significant gender predominance. 
Although in most cases benign, hormonally active pheo poses a real life threat due to the 
sympathetic system overstimulation. Malignant pheo constitutes 10–25% of all cases [2]. 
Given the rarity of this condition, therapeutic options are not well defined and those which are 
available are mostly palliative [3]. 
 
Case report 
We present a case of a Caucasian female diagnosed with malignant pheo, treated with 
surgery along with both cold and hot somatostatin analogues. In October 2006, at the age of 
51, she underwent an abdominal ultrasound (US) scan due to recurring pains of the lumbar 
area. A 109 x 89 x 92 mm mass of the left adrenal gland was visualized. Irregular 
echogenicity and focal necrosis were described (Fig. 1). Typical pheo-associated symptoms, 
such as paroxysmal hypertension, tachycardia, sweating, tremors or anxiety were not present 
at any time. Multiple blood pressure readings in 2006 during a hospitalization ranged up to 
120–130/80 mm Hg. 
A computed tomography (CT) scan performed in October 2006 confirmed the 
presence of a 90 x 95 x 120 mm lesion in the left adrenal gland with focal necrosis and 
irregular attenuation coefficient along with moderate enhancement after contrast 
administration. The edges were well defined and the tumour did not involve the adjoining 
tissues (pictures not available). Laboratory testing showed normal function of the adrenal 
cortex and medulla. Total metanephrine level in a 24-h urine sample was 300 µg (reference 
ranges < 1000 µg/24 h). 24-h fractionated metanephrines were not assessed since such testing 
was unavailable at our centre at the time. 
A classic adrenalectomy was performed in November 2006. The excised tumour 
measured 140 x 120 x 90 mm and weighed 430 grams. Pathologic evaluation indicated pheo 
with no invasion beyond the capsule. Immunohistochemical staining was positive for 
chromogranin A and synaptophysin. 
A CT scan performed in January 2007 showed no signs of recurrence; however, 
shortly after that the patient reported two tumours she palpated in the scar. In US two solid 
lesions in subcutaneous tissue were described. In March 2007 the nodules were excised and 
the histopathological examination indicated pheo. Diagnosis of malignant pheo was 
suspected. Bone scintigraphy performed in February 2008 revealed no pathological uptake. A 
routine, follow-up CT scan the patient underwent in May 2008. Examination revealed a 25 x 
29 x 36 mm mass in the left adrenal gland bed together with 2 tumours in the scar area and 
descending colon wall thickening with considerable narrowing. Hormonal evaluation revealed 
no catecholamine excess again. Genetic testing for RET, VHL, NF1, SDHB, SDHC and SDHD 
mutations was negative. 
Because of those findings our patient underwent a laparotomy in June 2008, when a 
left hemicolectomy was performed and the abdominal wall tumours were removed. The mass 
in the left adrenal bed was deemed inoperable due to infiltration of both superior mesenteric 
vein and left renal vessels. 
At that time, the diagnosis was unclear. The clinical picture could indicate both pheo-
paraganglioma syndrome and malignant pheo due to the fact that the masses appeared in the 
area that was previously operated on. However, malignant pheo was highly suspected. In 
order to investigate the therapeutic options the patient underwent a 123I-MIBI scintigraphy 
along with 99mHYNIC TOC and NeoSPECT 99mTc-HYNIC-TOC scans, the results of which 
indicated that somatostatin analogues would be the best option, with lanreotide as a first 
choice. 123I-MIBI was decided against due to insufficient tracer uptake. 
In September 2008 the patient presented with abdominal pain and underwent a CT 
scan. A large mass 10 x 9 x 6 cm in the right mid abdomen was revealed and a month later it 
was excised. Histopathologically, pheo was described and final diagnosis of malignant pheo 
was established (Fig. 2). 
Follow-up CT (December 2008) revealed two pathological masses in primary tumour bed. 
The larger one was 42 x 14 mm and the smaller one was 19 x 12 mm. Radiolabelled 
lanreotide (Y90-Lan) was administered in November 2008 and January 2009. In February 
2009 the patient underwent a surgical excision of a new pathological mass in the skin of left 
anterior superior iliac spine area. 
A month later she presented with pancytopenia which caused the diagnosis of multiple 
myeloma to be considered. Full diagnostic workup was performed and multiple myeloma was 
excluded. Pancytopenia was attributed to hot somatostatin analogue treatment, which was 
therefore discontinued. Because of abdominal pain, another abdominal CT was performed. 
Examination revealed progression of previously described tumours and new pathological 
mass in pelvis (left ovary area) measuring 38 x 31 mm (CT scans not available). 
In June 2009, after a consultation we decided on debulking surgery. Extensive 
procedure with tumour in left adrenal bed resection (in June 2008 described as nonoperative), 
left nephrectomy and anterio-superior rectal resection and partial small bowel resection was 
performed. Histopathologically, every resected tumour contained pheo tissue.  
Routine abdominal US revealed new pathological masses in skin and subcutaneous 
tissue. In May and September 2010 our patient underwent two surgical procedures. First, 
lesions in the abdominal wall were excised, and the second operation involved the removal of 
2 retroperitoneal tumours. “Cold analogue” lanreotide therapy was started in September 2010 
and was continued throughout the whole follow-up period. 
In February 2011 a positron emission tomography (PET) scan showed high risk of 
peritonitis carcinomatosa and therefore, in April 2011, a laparotomy was performed. At the 
time an intramural tumour of the rectum was removed together with 26 tumours from the 
retroperitoneum. 
In June 2011 pathological masses behind the front abdominal wall were discovered. 
No surgical procedure was performed. In March 2012 the patient presented with nausea, 
abdominal pain together with rapid increase in creatinine levels and oliguria, which led to the 
diagnosis of hydronephrosis. A double J stent was placed in the right ureter which alleviated 
the patient’s symptoms. A CT scan performed at that time revealed further disease 
progression with large tumour in primary tumour bed (85 x 65 x 100 mm), few peritoneal 
implants and new 17 mm pathological mass in pelvis compressing right ureter. The patient 
underwent a laparotomy. The perioperative period was complicated with a severe 
haemorrhage, which was fatal. Prior to the last laparotomy the patient was offered treatment 
with chemotherapy, which she declined. She had never had typical symptoms of pheo. All 
procedures are summarized in Table 1. 
 
Discussion 
Due to rarity and variability of clinical presentation, pheo is a real diagnostic challenge 
for physicians [2]. The clinical course may be highly variable and no definitive predictive 
factors of malignancy are currently available. Recent data shows that tumours with SDHB 
mutation present significantly higher rates of malignancy [4].Owing to the fact that a 
remarkable number of patients still die due to hormone overproduction, the main treatment 
objectives are controlling the tumour mass and hormonal symptoms [3]. Pheo is considered a 
secondary cause of hypertension, one that can be corrected surgically. Therefore it needs to be 
taken into account in every patient presenting with an adrenal tumour together with 
hypertension (paroxysmal or persistent). Even in the absence of typical symptoms and 
elevation of biochemical markers one cannot exclude pheo (malignant or benign) [5]. 
The diagnosis of malignancy can only be made by the discovery of distant metastases, 
direct invasion of surrounding tissues or presence of pheo in sites where chromaffin tissue is 
normally absent [6]. Pathologic markers are not predictive enough to be considered reliable in 
terms of tumour malignancy [2, 3]. Most common metastatic sites include liver, lungs, lymph 
nodes and bones [7]. Metastases may appear as long as 20 years after initial presentation, 
therefore long-term follow-up is mandatory [8]. 
Data concerning survival rates varies — some patients present a more aggressive 
clinical course and die within 5 years of the diagnosis, whereas others show no disease 
progression for many years despite not receiving any targeted therapy [2]. In the literature we 
reviewed, survival times ranged from1 year to 23 years [2, 9]. However, since there are no 
reliable prognostic factors, determining the aggressiveness of the clinical course is impossible. 
Therefore a dilemma naturally arises — whether to treat and when to treat. 
Given the rarity of malignant pheo, there definitely is a lack of prospective and 
randomized studies. Available data is not completely reliable as reports on efficacy of 
different treatment modalities are variable. Having analysed a number of reports, we feel that 
the following findings are worth mentioning. 
Chemotherapy seems to bring the most benefit to patients presenting with rapidly 
progressive disease rather than those with a more indolent clinical course [3], although 
Tanabe et al. found it to be more effective in the latter group [10].The use of CVD 
(cyclophosphamide, vincristine, dacarbazine) regimen is well-recognized. Its implementation 
was justified by the resemblance between chromaffin tumours and neuroblastomas [11]. 
Adverse effects are mostly mild, the most common being gastrointestinal symptoms, 
leukopenia and hepatic dysfunction. If there is no significant response (biochemical or 
tumoural) after 4–5 cycles of CVD, it should be discontinued [10]. For inoperable lesions or 
multiple hepatic metastases, transcatheter arterial embolization with concomitant 
administration of doxorubicin or mitomycin-C has been attempted [12, 13]. 
In the case of malignant pheo surgery should be considered as a treatment of choice 
for both primary tumours and metastases [14]. Its intent may be to cure the disease or alleviate 
hormonal as well as compression-related symptoms [15]. Moreover, debulking surgery may 
also improve response to later treatment [8, 15]. Prior to surgery, as for every other treatment 
in the case of a hormonally active disease, adequate alpha-adrenergic blockade is mandatory 
[16, 17]. This prevents intraoperative complications related to massive catecholamine release, 
such as a hypertensive crisis, arrhythmias and myocardial infarction. Although surgical 
resection is the only potentially curative approach, it is rarely feasible due to delayed 
diagnosis of malignancy. In some cases metastasectomy proved to be a sufficient treatment, 
leading to complete remission and patients remaining asymptomatic for years [18, 19]. Our 
patient underwent multiple debulking surgeries which, together with long-term lanreotide 
treatment, enabled the almost six-year follow-up that she achieved. Reducing tumour burden 
might have facilitated better outcome of lanreotide therapy since cold somatostatin analogues 
alone have not shown considerable efficacy in treatment of malignant pheo. 
Approximately 36% of patients diagnosed with malignant pheo are carriers of a 
hereditary germline mutation of SDHB (succinate dehydrogenase subunit B) [20]. Malignant 
pheos, particularly those associated with SHDB mutation, have been reported to be highly 
vascularized tumours. Therefore, antiangiogenic therapy with sunitinib was implemented. 
Although not curative, it can be an alternative for patients with progressive disease resistant to 
therapy or not eligible for other treatment modalities [20]. The effectiveness seems to be 
satisfying, as sunitinib was reported to lead to at least disease stabilization. Shen et al. 
described necrosis of majority of the metastatic masses as a result of this course of treatment 
[21]. Side effects included hypothyroidism, hypertension and haematological toxicity [9, 21, 
22]. 
123I-MIBG treatment has been attempted in various dose settings. According to Rose et 
al., repeated high-dose 131MIBG may be associated with long-term survival [23]. Single high-
dose administration was also proven effective. However, this kind of treatment may result in a 
high percentage of severe haematological toxicity. Multiple intermediate or low doses 
regimens were more tolerable and had a reduced rate of myelosuppression while still offering 
a chance of prolonged survival [24–27]. Even in the case of “non-responders” in terms of 
tumour shrinkage or biochemical parameters, this course of therapy brought considerable 
symptomatic relief, therefore improving the patients’ quality of life. In order to prevent 
hypothyroidism, thyroid blockade should be attempted even though it has been reported that 
despite potassium iodate use, tracer uptake to the thyroid is still visible on the scans [25]. 
If the lesions show sufficient tracer uptake on somatostatin receptor scintigraphy, 
treatment with somatostatin analogues may be attempted [27]. Generally, radioactive 
analogues are recommended, as “cold” ones have resulted in only transient responses. 
Lamarre-Cliche et al. proved that slow-release octreotide administered in the group of patients 
who did not undergo debulking surgery or receive other treatment such as MIBG or 
embolization appears to not be of sufficient effectiveness for the long-term treatment [28]. 
Moreover, it does not improve pheo-related symptoms significantly. Side effects of 
radioactive SST analogues are mainly haematological, as shown in the case of our patient, 
who became pancytopenic due to treatment with a hot SST analogue and had to be treated 
with non-labelled lanreotide instead. 
 
 
Conclusion 
The rarity of malignant pheochromocytoma, lack of definitive predictors of 
malignancy and the variability of clinical course pose a significant diagnostic and therapeutic 
challenge. Since data on treatment is so scarce, case reports are a valuable source of 
knowledge for clinicians. 
Debulking surgery may play a substantial role in prolonging the patients’ survival. 
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 Figure 1.  
 
 
Figure 2. 
Table 1. History of pheochromocytoma management 
History of pheochromocytoma management (precise dates in text) 
2006 Ultrasound — 108 x 88 x 92 mm tumour of left adrenal gland  
Abdominal CT — 90 x 95 x 120 mass of the left adrenal gland (focal necrosis, irregular 
attenuation coefficient, moderate enhancement after contrast administration, no 
involvement of adjoining structures) 
24-hour urine metoxycatocholamine levels — 300 µg  
Classic left adrenalectomy (tumour 140 x 120 x 90 mm, 430 g); histopathologically-
confirmed pheo 
2007 CT clear of any lesions in both adrenal areas 
Later 2 tumours in postoperative scar — on ultrasound 1.48 x 1.43 cm and 2.09 x 1.27 cm; 
histopathologically-confirmed pheo 
2008 Bone scintigraphy shows no pathological tracer accumulation  
2nd surgery — tumours in the scar excised histopathologically-confirmed pheo 
Abdominal CT — 25 x 29 x 36 mm mass in the left adrenal bed, 2 tumours in the 
abdominal wall, descending colon wall thickening with considerable luminal narrowing  
3rd surgery — left hemicolectomy, abdominal wall tumours excised, mass in the left adrenal 
bed considered inoperable; histopathologically-confirmed pheo 
Abdominal CT — right mid abdomen tumour, 2 abdominal wall tumours  
4th surgery — whole pathological mid abdominal mass excised, tumours in the abdominal 
wall considered inoperable histopathologically-confirmed pheo 
1st dose of Y-90-Lanreotide (1.15 GBq) 
2009 
 
2nd dose of Y-90-Lanreotide (1.2 GBq) 
5th surgery — nodule in the left anterior superior iliac spine area excised; 
histopathologically-confirmed pheo 
Pancytopenia attributed to hot somatostatin analogues treatment 
6th surgery — left nephrectomy, tumour previously considered inoperable resected, anterio-
superior rectal resection, partial small bowel resection; histopathologically-confirmed pheo 
in each localization 
2010 7th surgery — abdominal wall tumour excised histopathologically-confirmed pheo 
8th surgery — abdominal wall tumour and 2 retroperitoneal lesions excised; 
histopathologically-confirmed pheo 
Long-acting lanreotide therapy initiation 
2011 FDG-PET scan — high risk of peritonitis carcinomatosa, confirmed in a CT scan 
9th surgery — intramural tumour of the rectum and 26 retroperitoneal implants resected 
2012 Double J stent placed in the right ureter (obstructive hydronephrosis) 
CT — further disease progression 
10th laparotomy — severe haemorrhage turns out to be fatal 
CT — computed tomography; pheo — pheochromocytoma; Y-90-Lanreotide — yttrium-90-
labelled lanreotide; GBq — gigabecquerel; FDG-PET scan — fluorodeoxyglucose positron 
emission tomography 
